Gilead Sciences to launch authorized generics of two hepatitis C drugs
The authorized generics, announced amid HCV product pricing pressures, will cost $24,000 - less than one-third the branded drugs' prices - to reflect discounts given to payers.
Abbvie’s Viekira Pak Costs $6.5 Million a Year in Avoidable Costs, Puts Patients at Greater Risk
Abbvie’s Viekira Pak Costs $6.5 Million a Year in Avoidable Costs, Puts Patients at Greater Risk// // In January 2015, Advera Health released a Drug Safety Monitor analysis comparing the safety of then newly approved Hepatitis C drugs Viekira Pak to Harvoni and Solvaldi (hereafter just Harvoni). Our analysts concluded, …both Harvoni and Sovaldi appear […]
presented by
A Path to Healing: Discovering Arizona’s PTSD Treatment Centers
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
Did Express Scripts choose the right hepatitis C drug?
Last week’s blog post discussed the dangerous precedent that exclusivity deals between drug manufacturers and payers set. Deals like the one Express Scripts and AbbVie’s signed for discounted rates on the new Hepatitis C drug, Viekira Pak. I argued that these deals emphasize the payer trend of focusing on immediate savings rather than overall outcomes, […]